Clinical trials: Eruption
Acne Vulgaris
Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris
This is a randomized, comparator-controlled, single-blind, parallel-group study. The current study proposes to compare a fixed-dose combination product containing 3% benzoyl peroxide (BPO) and 1% clindamycin against a cream…
- Trial name
- NCT02058628
- Testing
- Clindamycin + BPO, Azelaic acid
- Where
- 11 sites in Germany
- Volunteers
- 222 people
- Sponsor
- GlaxoSmithKline
Acne Vulgaris
A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne
This is a 12 week clinical trial in subjects with acne vulgaris. Subjects will be randomized to NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel twice daily.
- Trial name
- NCT01844752
- Testing
- NVN1000 1% Gel, NVN1000 4% Gel, Vehicle Gel
- Where
- 3 sites in Dominican Republic, Honduras and 1 more
- Volunteers
- 153 people
- Sponsor
- Novan, Inc.
Acne Vulgaris
A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne
This study will compare two different acne treatment regimens for the treatment of acne. Half of participants will receive a cleanser and a light therapy mask, while half of the participants will receive a cleanser, a light…
- Trial name
- NCT03124381
- Testing
- Cleanser, Acne Mask, Cleanser, Gel-Cream, Acne Mask
- Where
- 2 sites in United States
- Volunteers
- 126 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Acne Vulgaris
Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, double-blinded, vehicle-controlled, parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GI148512 (benzoyl peroxide [BPO] 3% gel) when applied once daily…
- Trial name
- NCT01400932
- Testing
- GI148512, vehicle gel
- Where
- 19 sites in Japan
- Volunteers
- 360 people
- Sponsor
- GlaxoSmithKline
Acne Vulgaris
Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris
The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.
- Trial name
- NCT02832063
- Testing
- B244
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- AOBiome LLC
Acne Vulgaris
A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris
The purpose of this study is to evaluate the safety and tolerability of JNJ 10229570-AAA after a single topical application of JNJ 10229570-AAA 1.2% and 3.6% cream in Japanese participants with acne.
- Trial name
- NCT01492647
- Testing
- JNJ 10229570-AAA 1.2%, JNJ 10229570-AAA 3.6%, Color-matched vehicle containing 0 mg of JNJ 10229570-AAA
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Janssen Pharmaceutical K.K.
Acne Vulgaris
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
This study is to evaluate the safety, pharmacokinetics, and treatment effect for topically applied CABTREO lotion in pediatric participants ages 9 to 11 years, 11 months with Acne Vulgaris.
- Trial name
- NCT07524946
- Testing
- CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel
This will be an open-label study designed to assess the safety and plasma PK of topically applied IDP-126 Gel compared to Control Gel.
- Trial name
- NCT03653403
- Testing
- IDP-126 Gel, Control Gel
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Bausch Health Americas, Inc.
Acne
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to four dose levels in adult participants aged 18 to 45 years with…
- Trial name
- NCT06316297
- Testing
- Acne mRNA vaccine
- Where
- 94 sites in United States, Australia and 2 more
- Volunteers
- 800 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acne Vulgaris
BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1%…
- Trial name
- NCT02709096
- Testing
- BPX-01, 1% Topical Gel, BPX-01 Vehicle Gel
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- BioPharmX, Inc.
EGFR Inhibitor-Induced Skin Rash
Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy
Epidermal growth factor receptor inhibitor (EGFRI) therapy for cancer is associated with potentially severe face and trunk skin acneiform rash.
- Trial name
- NCT04239846
- Testing
- AC-701 Topical Gel 0.3%
- Where
- 2 sites in Taiwan
- Volunteers
- 74 people
- Sponsor
- TWi Biotechnology, Inc.
Acne Vulgaris
Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients
The purpose of this study is to evaluate the tolerability and safety and to determine whether FXFM244 Antibiotic Foam is effective in the treatment of Acne Vulgaris.
- Trial name
- NCT01362010
- Testing
- Topical Minocycline Foam FXFM244
- Where
- 3 sites in Israel
- Volunteers
- 150 people
- Sponsor
- Vyne Therapeutics Inc.